Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESYNAD: Methotrexate to Prevent Anti-Adalimumab Antibodies in Spondyloarthritis
NCT04360785Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate in spondyloarthritis (SpA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Anti-Adalimumab Antibodies at 6 months. Started Nov 2020; status: completed.
02
Drugs
methotrexate
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT04360785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360785.